Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data

Nathan Fewel PharmD, BCPS

Independent Researcher, VancoPK, LLC, Temple, TX, USA

Correspondence
Nathan Fewel, 1901 South 1st Street, Temple, TX 76504, USA.
Email: Nathan.Fewel@VA.gov

Funding information
N/a, this study did not receive any funding

Abstract
What is known and objective: The revised vancomycin monitoring guidelines recommend targeting an area under the curve (AUC) of 400–600 mg·hr/L for serious methicillin-resistant Staphylococcus aureus (MRSA) infections. An AUC can be measured by checking a peak and trough concentration at steady state; however, this requires obtaining an additional blood sample. The most practical way to perform AUC-guided dosing is by estimating an AUC from a steady-state trough. The purpose of this study was to compare AUCs estimated from trough-only data to AUCs calculated from peak and trough concentrations.

Methods: Steady-state peak and trough data were collected from an open-access clinical calculator VancoPK.com. Patients were included who had (1) peaks drawn ≥60 min after the end of infusion, (2) peak and trough levels drawn ≥4 h apart and (3) troughs drawn ≤4 h early or late. The population was randomized and divided into a model group and test group. A population equation for vancomycin volume of distribution (Vd) was derived and compared to other general adult Vd models. Accuracy and precision of estimated AUCs were measured with bias, root mean square error (RMSE) and Lin’s concordance correlation.

Results and discussion: A total of 2,500 adult patients were included in the model group and 1,843 were included in the test group. The derived Vd equation, Vd (L) = 0.29(age) +0.33(total BW in kg) +11, produced accurate and precise AUC estimates from trough-only data. The mean actual AUC and estimated AUC were 504 and 503, respectively, with a correlation of 0.926. The RMSE between estimated and actual AUCs was 47.7, meaning that over 95% of estimated AUCs were within 100 points of actual AUCs with the study’s Vd model. Other Vd models performed well for certain types of patients, depending on their body weight and age.

What is new and conclusion: There is limited evidence from large, robust populations regarding how to estimate Vd for general adult patients. Accuracy and precision of estimated AUCs depend on the applied population Vd model. The Vd model from the present study can be used for AUC-guided dosing with trough-only data which requires less blood work than peak-trough monitoring. AUC calculations are practical with the use of open-access websites.
1 | WHAT IS KNOWN AND OBJECTIVE

When taken at face value, vancomycin troughs are poor surrogates of the area under the curve (AUC).\(^1\) The revised vancomycin monitoring guidelines recommend targeting an AUC range of 400–600 mg*hr/L for serious methicillin-resistant \textit{Staphylococcus aureus} (MRSA) infections.\(^2\) With a vancomycin minimum inhibitory concentration (MIC) of 1 mg/L, a daily AUC ≥400 is needed for efficacy while a daily AUC >650 may increase the risk of acute kidney injury.\(^3\)

One of the preferred methods for AUC-guided dosing is by measuring a peak and trough when concentrations are at steady state. The levels can be used to calculate an elimination rate constant (Ke) and an apparent volume of distribution (Vd), which together equal vancomycin clearance (CLv). Equation (1).

\[
CL_v (L/hr) = V_d \times Ke \tag{1}
\]

At steady state, a snapshot of the daily AUC can be calculated from CLv based on a total daily dose (TDD). Equation (2).

\[
AUC_{24} = \frac{TDD}{CL_v} \tag{2}
\]

Although accurate, this method for AUC-guided dosing requires obtaining an additional blood sample at an appropriate time. One-compartment, first-order pharmacokinetic (PK) equations require peak levels to be drawn at least one hour after the end of infusion, and trough levels to be drawn at least 4 hr after the peak level.\(^2\)

Monitoring a trough near steady state is a practical way to estimate the AUC and provide AUC-guided dosing. This can be done by using Bayesian statistics or PK equations. The vancomycin guidelines define utilizing Bayesian software as a clinical option for some patients, but state that "more data are needed across different patient populations to confirm the viability of using trough-only data."\(^2\) Bayesian software programmes produce very different results, and their use is often limited by costly subscriptions.\(^4\)

The PK method uses analytical equations that produce consistent results; however, studies evaluating this approach for estimating AUCs have not been published previously. The primary issue of using trough-only data to estimate an AUC is that there is limited evidence for Vd models developed from large, robust populations. Most general adult Vd models are from studies that had fewer than 200 patients and had limited sampling of patients with extreme age or body weight.\(^5,6\)

The following intermittent IV infusion equation was first described by Sawchuk and Zaske in 1976 (Equation 3).\(^7,8\) When measuring a steady-state vancomycin level after distribution has finished, all variables in Equation 3 are known except for Vd and Ke.

\[
C_w = \frac{Dose \left( e^{−Ke(T−t)} \right) \left( 1 − e^{−Ke×T} \right)}{t_i \times Ke \times Vd \left( 1 − e^{−Ke×T} \right)} \tag{3}
\]

The first step to solve this equation is to estimate Vd from a population model. Next, Ke must be determined so that the calculated level from the equation, Css, matches the level that was measured. Once Vd and Ke have been calculated, then Equation 1 can be used to estimate CLv, and Equation 2 can be used to estimate an AUC from a total daily dose.

Solving this equation by hand or with non-kinetics software like Excel is not practical, but there are open-access websites that use this method.\(^9,10\) The purpose of this study was to compare the accuracy and precision of AUCs estimated from trough-only data to actual AUCs calculated from peak and trough concentrations.

2 | METHODS

Data were collected from the website VancoPK.com from June 2020 to May 2021. When users pressed the "calculate" button on the steady-state peak and trough calculator, the following data were gathered: the date and time, age, height, body weight, gender, serum creatinine, dose, dosing interval, infusion rate, steady-state peak and trough, and time from start of infusion to the peak and trough. Patient-specific Vd, Ke, CLv and AUC were calculated from the data using first-order, intermittent IV infusion equations.

Due to its simplicity and ease of clinical use, a one-compartment model was fit to the serum vancomycin concentrations.\(^2,8,11\) Patients were included who had (1) peaks drawn ≥60 min after the end of infusion, (2) peak and trough levels drawn ≥4 h apart and (3) troughs drawn ≤4 h early or late. The detailed data gathered for each patient allowed for duplicate and test data to be identified and removed. This was done by using Excel's remove duplicate tool and by sorting the data by the different variables. Only one unique patient for every peak-trough couplet was allowed.

Multiple regression was used to identify significant patient variables for the Vd model. The population was randomized by a computer and divided into a model group and test group. Excel's solver tool was used to optimize the Vd equation's coefficients by minimizing the sum of squared differences between the actual and estimated AUCs.

Other population Vd models were identified by searching PubMed and reviewing pharmacokinetics textbooks. General adult Vd models were included that were derived from robust populations. Models derived from special populations such as burn patients, patients with haematological malignancies, or patients admitted to intensive care were excluded because they often have a larger mean Vd compared to general adult patients.\(^5,6\)
To evaluate the Vd models, root mean square error (RMSE) was used as a measure of precision, and bias was used as a measure of accuracy. Lin’s concordance correlation coefficient was used to measure the association between estimated AUCs with actual AUCs. Analysis was done using Microsoft Excel.

### 3 | RESULTS AND DISCUSSION

The adult Vd models identified for comparison are listed in Table 1. In general, vancomycin Vd ranges from about 0.5 to 1.0 L/kg, with an average of about 0.7 L/kg.\(^8\),\(^12\),\(^13\) Out of the four models, the Tanaka model had the largest study population with 164 patients.\(^14\)

A total of 4,343 patients were included in the present study, with 1,224 females and 3,119 males (Table 2). Many patients were excluded because their vancomycin levels were not drawn appropriately: 1,210 patients had peak levels drawn less than 60 min after the end of infusion, and 509 patients had peak and trough levels drawn less than 4 h apart.

Multiple regression analysis found that age and body weight were significant factors for estimating Vd \((p < 0.001)\). Although most Vd models only include body weight, many studies have also identified age as a factor for predicting vancomycin Vd at steady state. This has been ascribed to changes in peripheral circulation and enhanced tissue binding of vancomycin in the elderly.\(^12\),\(^14\)–\(^18\)

Coefficients in the Vd equation were determined by randomizing the total population, selecting 2,500 patients for a model group and optimizing the coefficients to reduce the square difference between actual and estimated AUCs. The process was repeated 30 times to find average coefficient values (Table 3). Equation (4).

\[
Vd = 0.29 \text{ (age)} + 0.33 \text{(actual BW in kg)} + 11
\]  

The derived Vd equation reduced interindividual variability of Vd by 17.2% versus the population mean Vd of 61.1 L in the test group. The only other model to reduce variability was the Sanchez model which had a 13.5% reduction. Table 4 describes the accuracy and precision of AUCs estimated from the Vd models.

The Winter, Sanchez and study models all had low bias and strong correlation between actual and estimated AUCs for the overall test group \((N = 1,843)\). They had a root mean square error (RMSE) of about 50, meaning that about 68% of estimated AUCs were within 50 points of actual AUCs. With an estimated AUC of 500, the actual AUC was within 400–600 about 95% of the time (Figure 1).

The Tanaka and Birt models had greater bias, weaker correlations and were less precise for the overall test group. Model performance was also evaluated by examining patients who had an extreme body mass index (BMI) (Table 5).

---

**TABLE 1** General adult Vd models included for comparison

| Vd Formulas (L) | Sanchez\(^{14}\) | Vd = 0.283 × BW + 32.2 × (age/53.5) |
|----------------|-----------------|-----------------------------------|
| Winter\(^{13}\) | Vd = 0.70 L/kg  |                                    |
| Tanaka\(^{21}\) | Vd = 0.864 L/kg |                                    |
| Birt\(^{22}\)  | Vd = 0.54 L/kg  |                                    |

**TABLE 2** Population characteristics \((N = 4,343)\)

|                  | Median | Mean | \(±SD\) | Range  | Units |
|------------------|--------|------|---------|--------|-------|
| Age              | 64     | 61.8 | (15.8)  | 18–100 | years |
| Height           | 173    | 172  | (10.8)  | 137–213| cm    |
| Body weight      | 82     | 86   | (27)    | 33–227 | kg    |
| BMI              | 27.5   | 29.1 | (8.5)   | 13.1–84.4| kg/m\(^2\) |
| SCr              | 0.83   | 0.91 | (0.37)  | 0.5–4.3| mg/dl |
| Dose             | 1000   | 1116 | (315)   | 250–2500| mg    |
| Dosing interval  | 12     | 14.7 | (6.4)   | 6–72   | hrs   |
| Peak             | 26.5   | 27   | (6.8)   | 12.1–51.7| mcg/ml |
| Trough           | 13.5   | 13.8 | (4.6)   | 5–33   | mcg/ml |
| CLcr             | 88.9   | 94.7 | (41.3)  | 10.2–339| ml/min |
| Vd               | 57.2   | 60.8 | (22.2)  | 16.2–173| L     |
| Vd \(0.68\)     | 0.68   | 0.74 | (0.28)  | 0.20–2.55| L/kg  |
| Ke               | 0.07   | 0.078| (0.04)  | 0.003–0.25| hr\(^{-1}\) |
| CLv              | 4.01   | 4.35 | (2.07)  | 0.32–14.3| L/hr  |
| AUC              | 499    | 504  | (127)   | 184–1045| mg*hr/L |

---

**TABLE 3** Coefficients of the Vd equation

|                  | Coefficients \((±SD)\) | 95% CI |
|------------------|-------------------------|-------|
| Age              | 0.289 (0.015)           | 0.284–0.294 |
| Body weight (kg) | 0.334 (0.010)           | 0.33–0.338  |
| Intercept        | 10.8 (1.0)              | 10.4–11.2  |
TABLE 4
Estimated AUCs compared to actual AUCs in the test group (N = 1,843)

| Vd models | Mean trough-only AUC (±SD) | Bias | RMSE  | Concordance correlation |
|-----------|-----------------------------|------|-------|-------------------------|
| Present study | 503 (47.7) | 1.6  | 47.7  | 0.926                   |
| Sanchez   | 495 (49.5) | 9.6  | 50.4  | 0.918                   |
| Winter    | 500 (53.4) | 4.6  | 53.5  | 0.909                   |
| Tanaka    | 470 (51.1) | 34   | 61.4  | 0.882                   |
| Birt      | 544 (58.6) | -39.8| 70.8  | 0.856                   |

Note: Bias was calculated as the difference between the mean actual AUC of 504 and mean estimated AUCs; RMSE (root mean square error) was used as a measure of precision.

FIGURE 1
Actual AUCs compared to AUCs estimated from trough-only data (N = 1,843)

TABLE 5
Subgroup analysis of patients who had an extreme body mass index (BMI)

| Vd models | BMI kg/m² | Mean trough-only AUC (±SD) | Bias | RMSE  | Concordance correlation |
|-----------|-----------|-----------------------------|------|-------|-------------------------|
| Present study | <20  | 502 (51.2) | 1.6  | 51.1  | 0.927                   |
|            | ≥40     | 512 (39.2) | 7.8  | 39.9  | 0.943                   |
| Sanchez   | <20     | 493 (51.7) | 10.4 | 52.5  | 0.924                   |
|           | ≥40     | 511 (39.7) | 8.3  | 40.4  | 0.94                    |
| Winter    | <20     | 538 (58.8) | -35  | 68.2  | 0.88                    |
|           | ≥40     | 478 (40.7) | 42   | 58.4  | 0.884                   |
| Tanaka    | <20     | 502 (56.2) | 1.5  | 56.0  | 0.913                   |
|           | ≥40     | 455 (40.9) | 64.3 | 76.2  | 0.816                   |
| Birt      | <20     | 593 (64.7) | -89.8| 110.5 | 0.747                   |
|           | ≥40     | 512 (41.7) | 8.1  | 42.4  | 0.937                   |

Note: The BMI <20 group had a mean actual AUC of 503 and a sample size of 150 patients; the BMI ≥40 group had a mean actual AUC of 520 and a sample size of 176 patients.
Only the Sanchez and study models had low bias and good precision for both extreme BMI groups. The Winter model is commonly used in clinical practice but may be ideally suited for patients who have normal body weight because increased bias and decreased precision were observed for both extreme BMI groups.

The Birt model, 0.54 L/kg, worked very well for the BMI ≥40 group who had a mean Vd of 0.54 L/kg. This finding is supported by a study from Adane et al.\textsuperscript{19} who evaluated extremely obese patients and found a population Vd of 0.51 L/kg.

The Tanaka model, 0.864 L/kg, worked well for the low BMI group who had a mean Vd of 0.94 L/kg. This is supported by a study of Japanese adult patients who had a mean body weight of 55 kg and a population Vd of 1.1 L/kg.\textsuperscript{20} Subgroup analysis of patients who had an extreme age is described in Table 6.

The Sanchez and study models were the most accurate and least-biased models for the younger age group. For the elderly group, the Tanaka and study models functioned well, followed by the Sanchez and Winter models which had somewhat greater bias and less precision.

For simplicity, trough-only data were the focus of this study, but the PK method can be applied to any steady-state level drawn ≥60 min after the end of infusion. Analysis of peak-only data resulted in

| Vd models | Age  | Mean trough-only AUC (±SD) | Bias | RMSE | Concordance correlation |
|-----------|------|---------------------------|------|------|------------------------|
| Present study | 18–40 | 492 (54.5) | 1.8 | 54.4 | 0.924 |
|           | ≥80   | 496 (45.9) | 6.2 | 46.2 | 0.93     |
| Sanchez   | 18–40 | 513 (55.8) | −18.7 | 58.7 | 0.915     |
|           | ≥80   | 473 (45.5) | 29   | 53.8 | 0.906     |
| Winter    | 18–40 | 467 (56.6) | 27.1 | 62.6 | 0.901 |
|           | ≥80   | 520 (51.1) | −17.8 | 54.0 | 0.907 |
| Tanaka    | 18–40 | 436 (54.7) | 57.8 | 79.5 | 0.847     |
|           | ≥80   | 490 (48.1) | 12.5 | 49.6 | 0.918     |
| Birt      | 18–40 | 513 (61.4) | −19.2 | 64.2 | 0.9     |
|           | ≥80   | 566 (57.2) | −63.5 | 85.3 | 0.801     |

Note: The age 18–40 group had a mean actual AUC of 494 and a sample size of 216 patients; the age ≥80 group had a mean actual AUC of 502 and a sample size of 212 patients.
essentially the same precision (RMSE) and correlation values as trough-only data. However, bias with trough-only data was nearly the opposite of peak-only data. For example, the Tanaka model in the test group had a trough-only bias of 34 and a peak-only bias of −32 (Figure 2).

Hospitals can validate Vd models by measuring peak and trough levels in their patient populations. For example, a quality improvement project was approved by the research service at the Central Texas Veterans Health Care System (N = 65). As in the present study, the Winter, Sanchez and study models performed very well overall. Greater precision of the estimated AUCs was observed in the validation group, which was probably due to the elderly, overweight population who generally have larger volumes of distribution (Table 7).

### 4 WHAT IS NEW AND CONCLUSION

Vancomycin AUCs can be estimated from a single steady-state level with PK equations by using an estimated Vd. Accuracy and precision of the estimated AUCs depend on the applied Vd model. Until now, there has been limited evidence from large, robust populations regarding how to estimate Vd for general adult patients.

The Vd equation derived in this study, \( V_d = 0.29(\text{age}) + 0.33(\text{total BW in kg}) + 11 \), can be used to estimate an AUC with trough-only data for general adult patients. Other population Vd models can be used for certain types of patients, depending on their age and body weight. Monitoring one steady-state level requires less blood work and is more practical than peak-trough monitoring. The RMSE of the difference between the actual and estimated AUCs was about 50, meaning that about 68% of estimated AUCs were within 50 points of the actual AUCs. Dosage can be titrated to target an AUC near 500 to ensure that the actual AUC is within the recommended range of 400–600. Although AUC calculations are not practical by hand in a clinical setting, open-access website calculators are available.\(^6\)\(^9\)\(^10\)

### ACKNOWLEDGEMENTS

None.

### CONFLICT OF INTEREST

The authors have no conflicts of interest.

### PATIENT CONSENT STATEMENT

N/a, the data were retrospective and did not contain any protected health information.

---

**Table 7** Results from a validation group (N = 65, mean actual AUC = 492)

| Vd models | Mean trough-only AUC (±SD) | Bias | RMSE | Concordance correlation |
|-----------|---------------------------|------|------|-------------------------|
| Present study | 501 (35.9) | −9 | 36.7 | 0.936 |
| Sanchez | 489 (35.6) | 2.9 | 35.5 | 0.939 |
| Winter | 498 (42.5) | −6 | 42.6 | 0.914 |
| Tanaka | 472 (40.6) | 19.7 | 44.8 | 0.904 |
| Birt | 537 (46.9) | −45 | 64.7 | 0.828 |

---

**REFERENCES**

1. Lodise TP, Drusano G. Vancomycin area under the curve–guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: Putting the safety of our patients first. *Clin Infect Dis*. 2021;72(9):1497-1501.

2. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis*. 2020;71(6):1361-1364.

3. Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. *Clin Infect Dis*. 2019;69(11):1881-1887.

4. Broeker A, Nardecchia M, Klinker KP, et al. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. *Clin Microbiol Infect*. 2019;25(10):1286.e1-1286.e7.

5. Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. *Clin Pharmacokinet*. 2012;51(1):1-13.

6. Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, part 1: in adults. *Clin Pharmacokinet*. 2020;59(6):671-698.

7. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. *J Pharmacokinet Pharmacodyn*. 1976;4(2):183-195.

8. Bauer LA. The aminoglycoside antibiotics. In: Bauer LA, ed. *Applied Clinical Pharmacokinetics* (3rd Ed.). New York, NY: McGraw Hill; 2004:474-499.

9. Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. *Clin Infect Dis*. 2019;69(11):1881-1887.

10. Ambrose PJ, Winter ME. Vancomycin. In: *Basic Clinical Pharmacokinetics* (4th ed.). Philadelphia, PA: Lippincott Williams & Wilkins; 2004:451-476.

11. Winter ME. Vancomycin. In: *Basic Clinical Pharmacokinetics* (3rd ed.). Spokane, WA: Applied Therapeutics; 1994:474-499.

12. Sánchez JL, Dominguez AR, Lane JR, Anderson PO, Capparelli EV, Cornejo-Bravo JM. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. *Int J Clin Pharmacol Ther*. 2010;48(08):525-533.
15. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16(5):513-518.

16. Purwonugroho TA, Chulavatnatol S, Preechagoon Y, Chindavijak B, Malatham K, Bunuparadah P. Population pharmacokinetics of vancomycin in Thai patients. ScientificWorldJournal. 2012;2012:762649.

17. Guay DR, Vance-Bryan K, Gilliland S, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol. 1993;33(10):918-922.

18. Cutler NR, Narang PK, Lesko LJ, et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984;36(6):803-810.

19. Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127-139.

20. Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20(2):139-148.

21. Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother. 2010;54(2):778-782.

22. Birt JK, Chandler MH. Using clinical data to determine vancomycin dosing parameters. Ther Drug Monit. 1990;12:206-209.

How to cite this article: Fewel N. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data. J Clin Pharm Ther. 2021;00:1-7. https://doi.org/10.1111/jcpt.13474